269 related articles for article (PubMed ID: 9361721)
21. Hydroxyurea therapy in children severely affected with sickle cell disease.
Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
[TBL] [Abstract][Full Text] [Related]
22. Clinical and hematological responses to hydroxyurea in Sicilian patients with Hb S/beta-thalassemia.
Rigano P; Rodgers GP; Renda D; Renda MC; Aquino A; Maggio A
Hemoglobin; 2001 Feb; 25(1):9-17. PubMed ID: 11300353
[TBL] [Abstract][Full Text] [Related]
23. Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease.
de Montalembert M; Belloy M; Bernaudin F; Gouraud F; Capdeville R; Mardini R; Philippe N; Jais JP; Bardakdjian J; Ducrocq R; Maier-Redelsperger M; Elion J; Labie D; Girot R
J Pediatr Hematol Oncol; 1997; 19(4):313-8. PubMed ID: 9256830
[TBL] [Abstract][Full Text] [Related]
24. Sickle cell anemia with systemic lupus erythematosus: response to hydroxyurea therapy.
Shetty AK; Kumar SR; Gedalia A; Warrier RP
J Pediatr Hematol Oncol; 1998; 20(4):335-7. PubMed ID: 9703008
[TBL] [Abstract][Full Text] [Related]
25. Hydroxyurea for the treatment of sickle cell disease.
el-Hazmi MA; Warsy AS; al-Momen A; Harakati M
Acta Haematol; 1992; 88(4):170-4. PubMed ID: 1292305
[TBL] [Abstract][Full Text] [Related]
26. Effects of hydroxyurea on blood rheology in sickle cell anemia: A two-years follow-up study.
Lemonne N; Möckesch B; Charlot K; Garnier Y; Waltz X; Lamarre Y; Antoine-Jonville S; Etienne-Julan M; Hardy-Dessources MD; Romana M; Connes P
Clin Hemorheol Microcirc; 2017; 67(2):141-148. PubMed ID: 28759962
[TBL] [Abstract][Full Text] [Related]
27. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
Ware RE; Eggleston B; Redding-Lallinger R; Wang WC; Smith-Whitley K; Daeschner C; Gee B; Styles LA; Helms RW; Kinney TR; Ohene-Frempong K
Blood; 2002 Jan; 99(1):10-4. PubMed ID: 11756146
[TBL] [Abstract][Full Text] [Related]
28. Hydroxyurea therapy in sickle cell anemia patients in Curaçao, The Netherlands Antilles.
Saleh AW; Velvis HJ; Gu LH; Hillen HF; Huisman TH
Acta Haematol; 1997; 98(3):125-9. PubMed ID: 9352741
[TBL] [Abstract][Full Text] [Related]
29. Hydroxyurea therapy in sickle cell anemia patients aids to maintain oral fungal colonization balance.
Salvia AC; Figueiredo MS; Braga JA; Pereira DF; Brighenti FL; Koga-Ito CY
J Oral Pathol Med; 2013 Aug; 42(7):570-5. PubMed ID: 23278631
[TBL] [Abstract][Full Text] [Related]
30. Higher nocturnal and awake oxygen saturations in children with sickle cell disease receiving hydroxyurea therapy.
Narang I; Kadmon G; Lai D; Dhanju S; Kirby-Allen M; Odame I; Amin R; Lu Z; Al-Saleh S
Ann Am Thorac Soc; 2015 Jul; 12(7):1044-9. PubMed ID: 25970812
[TBL] [Abstract][Full Text] [Related]
31. Effects of hydroxyurea on hemoglobin F and water content in the red blood cells of dogs and of patients with sickle cell anemia.
Orringer EP; Blythe DS; Johnson AE; Phillips G; Dover GJ; Parker JC
Blood; 1991 Jul; 78(1):212-6. PubMed ID: 1712641
[TBL] [Abstract][Full Text] [Related]
32. Hydroxyurea for the treatment of sickle cell disease.
Segal JB; Strouse JJ; Beach MC; Haywood C; Witkop C; Park H; Wilson RF; Bass EB; Lanzkron S
Evid Rep Technol Assess (Full Rep); 2008 Mar; (165):1-95. PubMed ID: 18457478
[TBL] [Abstract][Full Text] [Related]
33. Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria.
Adeyemo TA; Diaku-Akinwunmi IN; Ojewunmi OO; Bolarinwa AB; Adekile AD
Hemoglobin; 2019 May; 43(3):188-192. PubMed ID: 31462098
[TBL] [Abstract][Full Text] [Related]
34. Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease.
Fucharoen S; Siritanaratkul N; Winichagoon P; Chowthaworn J; Siriboon W; Muangsup W; Chaicharoen S; Poolsup N; Chindavijak B; Pootrakul P; Piankijagum A; Schechter AN; Rodgers GP
Blood; 1996 Feb; 87(3):887-92. PubMed ID: 8562958
[TBL] [Abstract][Full Text] [Related]
35. Hydroxyurea in sickle cell disease patients from Eastern Saudi Arabia.
Al-Jam'a AH; Al-Dabbous IA
Saudi Med J; 2002 Mar; 23(3):277-81. PubMed ID: 11938415
[TBL] [Abstract][Full Text] [Related]
36. Low dose hydroxyurea is effective in reducing the incidence of painful crisis and frequency of blood transfusion in sickle cell anemia patients from eastern India.
Patel DK; Mashon RS; Patel S; Das BS; Purohit P; Bishwal SC
Hemoglobin; 2012; 36(5):409-20. PubMed ID: 22881992
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of pharmacological efficacy and safety of hydroxyurea in sickle cell disease: Study of a pediatric cohort from Chhattisgarh, India.
Lad H; Naskar S; Punyasri Pasupuleti SKDB; Nahrel R; Sihare P; Chandak GR; Patra PK
Pediatr Hematol Oncol; 2023 May; 40(4):395-406. PubMed ID: 36226857
[TBL] [Abstract][Full Text] [Related]
38. Effects of hydroxyurea treatment for patients with hemoglobin SC disease.
Luchtman-Jones L; Pressel S; Hilliard L; Brown RC; Smith MG; Thompson AA; Lee MT; Rothman J; Rogers ZR; Owen W; Imran H; Thornburg C; Kwiatkowski JL; Aygun B; Nelson S; Roberts C; Gauger C; Piccone C; Kalfa T; Alvarez O; Hassell K; Davis BR; Ware RE
Am J Hematol; 2016 Feb; 91(2):238-42. PubMed ID: 26615793
[TBL] [Abstract][Full Text] [Related]
39. Hydroxyurea in the treatment of sickle-cell anemia.
Howard LW; Kennedy LD
Ann Pharmacother; 1997 Nov; 31(11):1393-6. PubMed ID: 9391697
[TBL] [Abstract][Full Text] [Related]
40. Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium.
Haynes J; Obiako B; Hester RB; Baliga BS; Stevens T
Am J Physiol Heart Circ Physiol; 2008 Jan; 294(1):H379-85. PubMed ID: 17993595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
